請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4405
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭安理,郭明良 | |
dc.contributor.author | Yu-Chieh Tsai | en |
dc.contributor.author | 蔡育傑 | zh_TW |
dc.date.accessioned | 2021-05-14T17:42:05Z | - |
dc.date.available | 2017-09-25 | |
dc.date.available | 2021-05-14T17:42:05Z | - |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-19 | |
dc.identifier.citation | Abboud, M., Saghir, N. S., Salame, J., & Geara, F. B. (2010). Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine. Breast J, 16(6), 644-646. doi:10.1111/j.1524-4741.2010.00980.x
Abraham, R., Pagano, F., Gomella, L. G., & Baffa, R. (2007). Chromosomal deletions in bladder cancer: shutting down pathways. Front Biosci, 12, 826-838. Baumann, M., Krause, M., Dikomey, E., Dittmann, K., Dorr, W., Kasten-Pisula, U., & Rodemann, H. P. (2007). EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol, 83(3), 238-248. doi:10.1016/j.radonc.2007.04.006 Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., & Pao, W. (2008). Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res, 14(22), 7519-7525. doi:10.1158/1078-0432.ccr-08-0151 Beg, A. A., & Baltimore, D. (1996). An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science, 274(5288), 782-784. Begg, A. C., Stewart, F. A., & Vens, C. (2011). Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer, 11(4), 239-253. doi:10.1038/nrc3007 Billerey, C., Chopin, D., Aubriot-Lorton, M. H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., . . . Radvanyi, F. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol, 158(6), 1955-1959. doi:10.1016/s0002-9440(10)64665-2 Blomgren, H., Edsmyr, F., von Stedingk, L. V., & Wasserman, J. (1986). Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients. Biomed Pharmacother, 40(2), 50-54. Boeckman, H. J., Trego, K. S., & Turchi, J. J. (2005). Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res, 3(5), 277-285. doi:10.1158/1541-7786.mcr-04-0032 Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., . . . Ang, K. K. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354(6), 567-578. doi:10.1056/NEJMoa053422 Booth, C. M., Siemens, D. R., Li, G., Peng, Y., Kong, W., Berman, D. M., & Mackillop, W. J. (2014). Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clin Oncol (R Coll Radiol), 26(8), 506-514. doi:10.1016/j.clon.2014.05.007 Bowers, G., Reardon, D., Hewitt, T., Dent, P., Mikkelsen, R. B., Valerie, K., . . . Schmidt-Ullrich, R. K. (2001). The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene, 20(11), 1388-1397. doi:10.1038/sj.onc.1204255 Cao, N., Li, S., Wang, Z., Ahmed, K. M., Degnan, M. E., Fan, M., . . . Li, J. J. (2009). NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res, 171(1), 9-21. doi:10.1667/rr1472.1 Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., . . . Radvanyi, F. (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet, 23(1), 18-20. doi:10.1038/12615 Chakravarti, A., Winter, K., Wu, C. L., Kaufman, D., Hammond, E., Parliament, M., . . . Shipley, W. (2005). Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 62(2), 309-317. doi:10.1016/j.ijrobp.2004.09.047 Chen, D. J., & Nirodi, C. S. (2007). The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res, 13(22 Pt 1), 6555-6560. doi:10.1158/1078-0432.ccr-07-1610 Chen, R. C., Shipley, W. U., Efstathiou, J. A., & Zietman, A. L. (2013). Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw, 11(8), 952-960. Chinnaiyan, P., Huang, S., Vallabhaneni, G., Armstrong, E., Varambally, S., Tomlins, S. A., . . . Harari, P. M. (2005). Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res, 65(8), 3328-3335. doi:10.1158/0008-5472.can-04-3547 Colquhoun, A. J., McHugh, L. A., Tulchinsky, E., Kriajevska, M., & Mellon, J. K. (2007). Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo. J Radiat Res, 48(5), 351-360. Colquhoun, A. J., & Mellon, J. K. (2004). Epidermal growth factor receptor (EGFR) blockade with Tarceva (TM) (Erlotinib) potentiates the antitumor effect of ionizing radiation in bladder cancer cell lines. Journal of Urology, 171(4), 252-252. Retrieved from <Go to ISI>://WOS:000220495500948 Comprehensive molecular characterization of urothelial bladder carcinoma. (2014). Nature, 507(7492), 315-322. doi:10.1038/nature12965 Coppin, C. M., Gospodarowicz, M. K., James, K., Tannock, I. F., Zee, B., Carson, J., . . . Sullivan, L. D. (1996). Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 14(11), 2901-2907. Cui, Y. H., Suh, Y., Lee, H. J., Yoo, K. C., Uddin, N., Jeong, Y. J., . . . Lee, S. J. (2015). Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor. Oncogene. doi:10.1038/onc.2014.466 Das, A. K., Chen, B. P., Story, M. D., Sato, M., Minna, J. D., Chen, D. J., & Nirodi, C. S. (2007). Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res, 67(11), 5267-5274. doi:10.1158/0008-5472.can-07-0242 Das, A. K., Sato, M., Story, M. D., Peyton, M., Graves, R., Redpath, S., . . . Nirodi, C. S. (2006). Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res, 66(19), 9601-9608. doi:10.1158/0008-5472.can-06-2627 Dent, P., Yacoub, A., Fisher, P. B., Hagan, M. P., & Grant, S. (2003). MAPK pathways in radiation responses. Oncogene, 22(37), 5885-5896. doi:10.1038/sj.onc.1206701 di Martino, E., L'Hote, C. G., Kennedy, W., Tomlinson, D. C., & Knowles, M. A. (2009). Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene, 28(48), 4306-4316. doi:10.1038/onc.2009.280 Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., . . . Rodemann, H. P. (2005). Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem, 280(35), 31182-31189. doi:10.1074/jbc.M506591200 Dittmann, K., Mayer, C., & Rodemann, H. P. (2005). Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol, 76(2), 157-161. doi:10.1016/j.radonc.2005.06.022 Dominguez-Escrig, J. L., Kelly, J. D., Neal, D. E., King, S. M., & Davies, B. R. (2004). Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res, 10(14), 4874-4884. doi:10.1158/1078-0432.ccr-04-0034 Dungo, R. T., & Keating, G. M. (2013). Afatinib: First Global Approval. Drugs. doi:10.1007/s40265-013-0111-6 Dyrskjot, L., Thykjaer, T., Kruhoffer, M., Jensen, J. L., Marcussen, N., Hamilton-Dutoit, S., . . . Orntoft, T. F. (2003). Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet, 33(1), 90-96. doi:10.1038/ng1061 Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., . . . Cote, R. J. (1994). Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med, 331(19), 1259-1264. doi:10.1056/nejm199411103311903 Fleischmann, A., Rotzer, D., Seiler, R., Studer, U. E., & Thalmann, G. N. (2011). Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol, 60(2), 350-357. doi:10.1016/j.eururo.2011.05.035 Gandour-Edwards, R., Lara, P. N., Jr., Folkins, A. K., LaSalle, J. M., Beckett, L., Li, Y., . . . DeVere-White, R. (2002). Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer, 95(5), 1009-1015. doi:10.1002/cncr.10808 Goebell, P. J., & Knowles, M. A. (2010). Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol, 28(4), 409-428. doi:10.1016/j.urolonc.2010.04.003 Golding, S. E., Rosenberg, E., Neill, S., Dent, P., Povirk, L. F., & Valerie, K. (2007). Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res, 67(3), 1046-1053. doi:10.1158/0008-5472.can-06-2371 Gonzalez, J. E., Barquinero, J. F., Lee, M., Garcia, O., & Casaco, A. (2012). Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther, 13(2), 71-76. doi:10.4161/cbt.13.2.18439 Gow, C. H., Chien, C. R., Chang, Y. L., Chiu, Y. H., Kuo, S. H., Shih, J. Y., . . . Yang, P. C. (2008). Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res, 14(1), 162-168. doi:10.1158/1078-0432.ccr-07-1468 Hamilton, E., Blackwell, K., Hobeika, A. C., Clay, T. M., Broadwater, G., Ren, X. R., . . . Morse, M. A. (2012). Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med, 10, 28. doi:10.1186/1479-5876-10-28 Harrington, K. J., El-Hariry, I. A., Holford, C. S., Lusinchi, A., Nutting, C. M., Rosine, D., . . . Bourhis, J. (2009). Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol, 27(7), 1100-1107. doi:10.1200/jco.2008.17.5349 Hernandez, S., Lopez-Knowles, E., Lloreta, J., Kogevinas, M., Amoros, A., Tardon, A., . . . Real, F. X. (2006). Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol, 24(22), 3664-3671. doi:10.1200/jco.2005.05.1771 Herr, H. W., Dotan, Z., Donat, S. M., & Bajorin, D. F. (2007). Defining optimal therapy for muscle invasive bladder cancer. J Urol, 177(2), 437-443. doi:10.1016/j.juro.2006.09.027 Hirsh, V. (2011). Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol, 7(7), 817-825. doi:10.2217/fon.11.62 Horiguchi, Y., Kikuchi, E., Ozu, C., Nishiyama, T., Oyama, M., Horinaga, M., . . . Tachibana, M. (2008). Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments. Hum Cell, 21(3), 57-63. doi:10.1111/j.1749-0774.2008.00055.x Huang, S. M., & Harari, P. M. (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res, 6(6), 2166-2174. Hurst, C. D., Platt, F. M., Taylor, C. F., & Knowles, M. A. (2012). Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin Cancer Res, 18(21), 5865-5877. doi:10.1158/1078-0432.ccr-12-1807 James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., . . . Huddart, R. A. (2012). Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med, 366(16), 1477-1488. doi:10.1056/NEJMoa1106106 Jimenez, R. E., Hussain, M., Bianco, F. J., Jr., Vaishampayan, U., Tabazcka, P., Sakr, W. A., . . . Grignon, D. J. (2001). Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res, 7(8), 2440-2447. Kachnic, L. A., Kaufman, D. S., Heney, N. M., Althausen, A. F., Griffin, P. P., Zietman, A. L., & Shipley, W. U. (1997). Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol, 15(3), 1022-1029. Kandel, E. S., Skeen, J., Majewski, N., Di Cristofano, A., Pandolfi, P. P., Feliciano, C. S., . . . Hay, N. (2002). Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol, 22(22), 7831-7841. Kassouf, W., Black, P. C., Tuziak, T., Bondaruk, J., Lee, S., Brown, G. A., . . . Dinney, C. P. (2008). Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol, 179(1), 353-358. doi:10.1016/j.juro.2007.08.087 Kaufman, D. S., Shipley, W. U., & Feldman, A. S. (2009). Bladder cancer. Lancet, 374(9685), 239-249. doi:10.1016/s0140-6736(09)60491-8 Kawamoto, A., Yokoe, T., Tanaka, K., Saigusa, S., Toiyama, Y., Yasuda, H., . . . Kusunoki, M. (2012). Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep, 27(1), 51-57. doi:10.3892/or.2011.1485 Kiemeney, L. A., Sulem, P., Besenbacher, S., Vermeulen, S. H., Sigurdsson, A., Thorleifsson, G., . . . Stefansson, K. (2010). A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet, 42(5), 415-419. doi:10.1038/ng.558 King, F. W., Skeen, J., Hay, N., & Shtivelman, E. (2004). Inhibition of Chk1 by activated PKB/Akt. Cell Cycle, 3(5), 634-637. Kirshner, J., Jobling, M. F., Pajares, M. J., Ravani, S. A., Glick, A. B., Lavin, M. J., . . . Barcellos-Hoff, M. H. (2006). Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res, 66(22), 10861-10869. doi:10.1158/0008-5472.can-06-2565 Knowles, M. A., & Hurst, C. D. (2015). Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer, 15(1), 25-41. doi:10.1038/nrc3817 Krause, M., Gurtner, K., Deuse, Y., & Baumann, M. (2009). Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int J Radiat Biol, 85(11), 943-954. doi:10.3109/09553000903232835 Kriegs, M., Kasten-Pisula, U., Rieckmann, T., Holst, K., Saker, J., Dahm-Daphi, J., & Dikomey, E. (2010). The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst), 9(8), 889-897. doi:10.1016/j.dnarep.2010.05.005 Kruger, S., Weitsch, G., Buttner, H., Matthiensen, A., Bohmer, T., Marquardt, T., . . . Bohle, A. (2002). HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer, 102(5), 514-518. doi:10.1002/ijc.10731 Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., . . . Wong, K. K. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27(34), 4702-4711. doi:10.1038/onc.2008.109 Liang, K., Lu, Y., Jin, W., Ang, K. K., Milas, L., & Fan, Z. (2003). Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther, 2(11), 1113-1120. Lindgren, D., Frigyesi, A., Gudjonsson, S., Sjodahl, G., Hallden, C., Chebil, G., . . . Hoglund, M. (2010). Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res, 70(9), 3463-3472. doi:10.1158/0008-5472.can-09-4213 Lipponen, P., Eskelinen, M., Syrjanen, S., Tervahauta, A., & Syrjanen, K. (1991). Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol, 20(3), 238-242. Liu, W., Huang, Y. J., Liu, C., Yang, Y. Y., Liu, H., Cui, J. G., . . . Li, B. L. (2014). Inhibition of TBK1 attenuates radiation-induced epithelial-mesenchymal transition of A549 human lung cancer cells via activation of GSK-3beta and repression of ZEB1. Lab Invest, 94(4), 362-370. doi:10.1038/labinvest.2013.153 Loehrer, P. J., Sr., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., . . . et al. (1992). A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol, 10(7), 1066-1073. Lokeshwar, S. D., Ruiz-Cordero, R., Hupe, M. C., Jorda, M., & Soloway, M. S. (2015). Impact of 2004 ISUP/WHO classification on bladder cancer grading. World J Urol. doi:10.1007/s00345-015-1548-x Maddineni, S. B., Sangar, V. K., Hendry, J. H., Margison, G. P., & Clarke, N. W. (2005). Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer, 92(1), 125-130. doi:10.1038/sj.bjc.6602299 Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., . . . Nukiwa, T. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362(25), 2380-2388. doi:10.1056/NEJMoa0909530 Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Baldini, E. H., . . . Sequist, L. V. (2011). Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist, 16(6), 886-895. doi:10.1634/theoncologist.2011-0040 Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell, 129(7), 1261-1274. doi:10.1016/j.cell.2007.06.009 Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y. M., Park, K., Kim, S. W., . . . Yang, J. C. (2012). Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol, 13(5), 528-538. doi:10.1016/s1470-2045(12)70087-6 Miyamoto, H., Miller, J. S., Fajardo, D. A., Lee, T. K., Netto, G. J., & Epstein, J. I. (2010). Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int, 60(1), 1-8. doi:10.1111/j.1440-1827.2009.02477.x Moneef, M. A., Sherwood, B. T., Bowman, K. J., Kockelbergh, R. C., Symonds, R. P., Steward, W. P., . . . Jones, G. D. (2003). Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity. Br J Cancer, 89(12), 2271-2276. doi:10.1038/sj.bjc.6601333 Morris, Z. S., & Harari, P. M. (2014). Interaction of radiation therapy with molecular targeted agents. J Clin Oncol, 32(26), 2886-2893. doi:10.1200/jco.2014.55.1366 Murakami, H., Tamura, T., Takahashi, T., Nokihara, H., Naito, T., Nakamura, Y., . . . Yamamoto, N. (2012). Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol, 69(4), 891-899. doi:10.1007/s00280-011-1738-1 Neal, D. E., Sharples, L., Smith, K., Fennelly, J., Hall, R. R., & Harris, A. L. (1990). The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65(7), 1619-1625. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. (2005). Eur Urol, 48(2), 202-205; discussion 205-206. doi:10.1016/j.eururo.2005.04.006 Nicolle, G., Daher, A., Maille, P., Vermey, M., Loric, S., Bakkar, A., . . . Chopin, D. K. (2006). Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res, 12(9), 2937-2943. doi:10.1158/1078-0432.ccr-05-2148 No, M., Choi, E. J., & Kim, I. A. (2009). Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther, 8(24), 2351-2361. Patel, S. G., Cohen, A., Weiner, A. B., & Steinberg, G. D. (2015). Intravesical therapy for bladder cancer. Expert Opin Pharmacother, 16(6), 889-901. doi:10.1517/14656566.2015.1024656 Pietras, R. J., Poen, J. C., Gallardo, D., Wongvipat, P. N., Lee, H. J., & Slamon, D. J. (1999). Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res, 59(6), 1347-1355. Prasad, S. M., Decastro, G. J., & Steinberg, G. D. (2011). Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol, 8(11), 631-642. doi:10.1038/nrurol.2011.144 Puc, J., Keniry, M., Li, H. S., Pandita, T. K., Choudhury, A. D., Memeo, L., . . . Parsons, R. (2005). Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell, 7(2), 193-204. doi:10.1016/j.ccr.2005.01.009 Quesnelle, K. M., & Grandis, J. R. (2011). Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res, 17(18), 5935-5944. doi:10.1158/1078-0432.ccr-11-0370 Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., & Bonner, W. M. (1998). DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem, 273(10), 5858-5868. Sambade, M. J., Camp, J. T., Kimple, R. J., Sartor, C. I., & Shields, J. M. (2009). Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol, 93(3), 639-644. doi:10.1016/j.radonc.2009.09.006 Sambade, M. J., Kimple, R. J., Camp, J. T., Peters, E., Livasy, C. A., Sartor, C. I., & Shields, J. M. (2010). Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys, 77(2), 575-581. doi:10.1016/j.ijrobp.2009.12.063 Sato, S., Kajiyama, Y., Sugano, M., Iwanuma, Y., Sonoue, H., Matsumoto, T., . . . Tsurumaru, M. (2005). Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys, 61(1), 203-211. doi:10.1016/j.ijrobp.2004.05.017 Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103(2), 211-225. Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., . . . Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 31(27), 3327-3334. doi:10.1200/jco.2012.44.2806 Singer, S., Ziegler, C., Schwalenberg, T., Hinz, A., Gotze, H., & Schulte, T. (2013). Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer, 21(5), 1383-1393. doi:10.1007/s00520-012-1680-8 Sjodahl, G., Lauss, M., Lovgren, K., Chebil, G., Gudjonsson, S., Veerla, S., . . . Hoglund, M. (2012). A molecular taxonomy for urothelial carcinoma. Clin Cancer Res, 18(12), 3377-3386. doi:10.1158/1078-0432.ccr-12-0077-t Sjodahl, G., Lovgren, K., Lauss, M., Patschan, O., Gudjonsson, S., Chebil, G., . . . Hoglund, M. (2013). Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol, 183(3), 681-691. doi:10.1016/j.ajpath.2013.05.013 Smith, H., Weaver, D., Barjenbruch, O., Weinstein, S., & Ross, G., Jr. (1989). Routine excretory urography in follow-up of superficial transitional cell carcinoma of bladder. Urology, 34(4), 193-196. Toulany, M., Dittmann, K., Baumann, M., & Rodemann, H. P. (2005). Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol, 74(2), 117-129. doi:10.1016/j.radonc.2004.11.008 Toulany, M., Minjgee, M., Kehlbach, R., Chen, J., Baumann, M., & Rodemann, H. P. (2010). ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. Radiother Oncol, 97(2), 338-345. doi:10.1016/j.radonc.2010.03.008 Tsai, Y. C., Ho, P. Y., Tzen, K. Y., Tuan, T. F., Liu, W. L., Cheng, A. L., . . . Cheng, J. C. (2015). Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells. Mol Cancer Ther. doi:10.1158/1535-7163.mct-13-0951 Tsai, Y. C., Yeh, C. H., Tzen, K. Y., Ho, P. Y., Tuan, T. F., Pu, Y. S., . . . Cheng, J. C. (2013). Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. Eur J Cancer, 49(6), 1458-1466. doi:10.1016/j.ejca.2012.10.020 von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., . . . Arning, M. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 23(21), 4602-4608. doi:10.1200/jco.2005.07.757 Winquist, E., Kirchner, T. S., Segal, R., Chin, J., & Lukka, H. (2004). Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol, 171(2 Pt 1), 561-569. doi:10.1097/01.ju.0000090967.08622.33 Wu, X. R. (2005). Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer, 5(9), 713-725. doi:10.1038/nrc1697 Wu, Y. L., Zhou, C., Hu, C. P., Feng, J., Lu, S., Huang, Y., . . . Geater, S. L. (2014). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 15(2), 213-222. doi:10.1016/s1470-2045(13)70604-1 Yan, S., Wang, Y., Yang, Q., Li, X., Kong, X., Zhang, N., . . . Kong, B. (2013). Low-dose radiation-induced epithelial-mesenchymal transition through NF-kappaB in cervical cancer cells. Int J Oncol, 42(5), 1801-1806. doi:10.3892/ijo.2013.1852 Yan, Y., Lu, Y., Wang, M., Vikis, H., Yao, R., Wang, Y., . . . You, M. (2006). Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res, 4(12), 971-981. doi:10.1158/1541-7786.mcr-06-0086 Yu, H. J., Tsai, T. C., Hsieh, T. S., & Chiu, T. Y. (1992). Characterization of a newly established human bladder carcinoma cell line, NTUB1. J Formos Med Assoc, 91(6), 608-613. Zhang, S., Zheng, X., Huang, H., Wu, K., Wang, B., Chen, X., & Ma, S. (2015). Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4405 | - |
dc.description.abstract | 膀胱癌是全世界與台灣男性第九常見的惡性腫瘤。對許患有局部肌肉侵襲性膀胱癌的病人,標準的膀胱根除手術並不可行。許多研究的焦點放在如何在”膀胱保存”的治療基準下善用放射線治療。然而相較於膀胱根除手術,放射線治療肌肉侵襲性膀胱癌病人的長期存活率低了約10%。傳統上化學治療藥物被用來當成放射增敏劑,但這樣的治療有許多廣為人知的毒性。因此我們有很強大的需求尋找能夠增進膀胱癌放射治療效果,又不增加毒性的藥物。
一個可以增進膀胱癌放射治療效果的合理方法,是同時使用抑制放射治療相關信息傳導路徑的標靶藥物。表皮生長因子受體(EGFR)是其中最重要的。Cetuximab是一個抑制EGFR的單株抗體,它已被證明在頭頸癌病人身上併用放射治療,可以增加療效。至於膀胱癌,gefitinib是一個EGFR的酪胺酸激酶抑制劑,它被顯示在膀胱癌的細胞模式有中等的放射增敏效果,而在膀胱癌的活體模式則只有些微的放射增敏效果。因此這個主題值得後續的研究。 在前驅性研究中我測試了包括erlotinib (EGFR抑制劑)、trastuzumab (HER2抑制劑)和lapatinib (EGFR/HER2抑制劑) 在膀胱癌細胞的放射增敏效果,可惜沒有一個有好的發展潛力。反而是afatinib,一個新一代可以同時抑制EGFR和HER2的酪胺酸激酶抑制劑,比較有前途。 在老鼠膀胱癌模式中,我第一次展示了在膀胱癌的細胞及活體模式中,afatinib都是一個有效的放射增敏劑。這個部分的動物實驗是在免疫正常的老鼠體內進行,比較類似人類的生理狀態。Afatinib似乎抑制了放射活化的EGFR與HER2信息,並增加了細胞DNA傷害與凋亡。 基於以上的發現,我假設在膀胱癌細胞,同時抑制EGFR和HER2酪胺酸激酶活性的afatinib,相較於只抑制EGFR酪胺酸激酶活性的erlotinib,會有較佳的放射增敏性。 為了確認這個假說,第一代的EGFR酪胺酸激酶抑制劑erlotinib和第二代的afatinib,第一次在人類膀胱癌細胞中被拿來比較它們的放射增敏性。我展示了在人類膀胱癌的細胞及活體模式中erlotinib的放射增敏性的不足以及afatinib優越的放射增敏效果。在HER2被抑制的人類膀胱癌細胞中,可以看到erlotinib顯示了放射增敏效果,所以可能是因為EGFR和HER2對放射敏感性有協同作用,讓afatinib雙重抑制的特性才會變得有效。我也展示了對EGFR-HER2異源雙體的抑制可能是afatinib放射增敏性機轉的證據。 在”展望”中我提到如何繼續這個研究主題,以及怎樣應用到臨床上。我希望這個研究的結果可以協助達成”增進膀胱癌放射治療效果,又不增加毒性”的目標。 | zh_TW |
dc.description.abstract | Bladder cancer is the ninth most common cancer in the world and in Taiwanese male population. For many patients with localized muscle-invasive bladder cancer, radical cystectomy is not a feasible treatment, and considerable interest was focused on the optimal use of radiotherapy in ”bladder preservation” protocol. However, the long-term survival of patients receiving radiation-based therapy in muscle invasive bladder cancer is about 10% inferior to patients receiving standard radical cystectomy. Traditionally chemotherapeutic agents are used as radiosensitizer but they have many well-known toxicities. Therefore, there is a strong need to find agents enhancing the radiation effect in urinary bladder cancer treatment while not increasing the toxicities.
A reasonable way to enhance the outcome of radiotherapy is by concomitantly using agents that inhibit radiation-activated signaling pathways. Epidermal growth factor receptor (EGFR) is the most important target. Cetuximab, an anti-EGFR antibody, has shown clinical benefit in head and neck cancer when combined with radiotherapy. In bladder cancer, gefitinib, an EGFR tyrosine kinase inhibitor (TKI), has moderate in vitro and marginal in vivo radiosensitizing activities. Therefore the topic deserves further investigation. In pilot study, I tested the radiosensitizing activities of erlotinib (EGFR inhibitor), trastuzumab (HER2 inhibitor) and lapatinib (EGFR/HER2 inhibitor) in bladder cancer cells. None of them showed good potential. Instead, afatinib, a new-generation EGFR inhibitor with activity against both EGFR and HER2, is more promising. In murine bladder cancer model, I demonstrated for the first time the in vitro and in vivo radiosensitizing activity of afatinib, an EGFR/HER2 dual inhibitor. The animal study was performed in immunocompetent mice and mimic human physiologic status. Afatinib likely mediates its effect on bladder cancer cells by suppressing radiation-activated EGFR and HER2 signals and thereby causing enhanced DNA damage and cell apoptosis. Based on the findings I hypothesized that in bladder cancer cells, the concomitant inhibition of EGFR and HER2 tyrosine kinase activity by afatinib has greater radiosensitizing activity than the inhibition of EGFR tyrosine kinase activity alone by erlotinib To confirm the hypothesis, in human bladder cancer model the radiosensitizing effects of different generations of clinically useful EGFR TKIs were compared for the first time. I showed the inadequacy of EGFR inhibition alone and the advantage of concomitant blockade of radiation-activated EGFR and HER2 signaling to inhibit the in vitro and in vivo growth of bladder cancer cells. The radiosensitizing effect of an EGFR inhibitor was much higher in HER2 knocked-down than wild-type cells, therefore HER2 may play a synergistic role with EGFR in determining radiosensitivity. I also showed evidence to support that receptor heterodimerization plays an important role in the radiosensitizing effect of afatinib. In Prospect I mentioned how to continue current project and apply the data to clinical use. I hope that the results of this study can help to meet the need of enhancing the radiation effect in urinary bladder cancer treatment while not increasing the toxicities. | en |
dc.description.provenance | Made available in DSpace on 2021-05-14T17:42:05Z (GMT). No. of bitstreams: 1 ntu-104-D95421013-1.pdf: 4087794 bytes, checksum: 9a5a29555cc1a871ee2f17bcc8fc6f4a (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員會審定書 i
Acknowledgement ii Table of Contents iii List of Figures v List of Tables viii Abbreviation ix Abstract (Chinese) xii Abstract (English) xiv CHAPTER ONE: INTRODUCTION 1.1 Clinical Overview of Bladder Cancer 1 1.2 Molecular Biology of Bladder Cancer 10 1.3 Radiation Effect and Signal Transduction Pathways 14 1.4 New-generation ErbB Family Inhibitors as Radiosensitizers 17 1.5 Hypothesis and Experimental Design 19 CHAPTER TWO: PILOT STUDY 2.1 Rationale and Approach 20 2.2 Materials and Methods 20 2.3 Results 21 CHAPTER THREE: RADIOSENSITIZING EFFECT OF AFATINIB IN A MURINE BLADDER CARCINOMA MODEL 3.1 Rationale and Approach 25 3.2 Materials and Methods 26 3.3 Results 32 CHAPTER FOUR: RADIOSENSITIZING EFFECT OF AFATINIB IN HUMAN BLADDER CANCER MODELS 4.1 Rationale and Approach 41 4.2 Materials and Methods 42 4.3 Results 49 CHAPTER FIVE: DISCUSSION 5.1 Pilot study 67 5.2 Murine Bladder Cancer Model 69 5.3 Human Bladder Cancer Model 74 5.4 Unfinished Study: Mutant EGFR - Related Research 78 CHAPTER SIX: PROSPECT 6.1 Radiosensitizing Activity of Afatinib and Microenvironment 83 6.2 Clinical Application 87 REFERENCE 90 APPENDIX 110 | |
dc.language.iso | en | |
dc.title | 利用新一代EGFR酪氨酸激酶抑制劑為放射增敏劑,用於膀胱癌的治療 | zh_TW |
dc.title | Utilizing New-Generation EGFR Tyrosine Kinase Inhibitor as Radiosensitizer in the Treatment of Urinary Bladder Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 彭汪嘉康,楊志新,黃正仲,周祖述 | |
dc.subject.keyword | EGFR,HER2,放射治療,膀胱癌, | zh_TW |
dc.subject.keyword | EGFR,HER2,Radiotherapy,Bladder cancer, | en |
dc.relation.page | 114 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2015-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf | 3.99 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。